Ost-müük Novo Nisk Adr Repsg 1 - NVO CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.48 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Novo Nordisk A/S ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Eelmine sulgemine* | 137.65 |
Avatud* | 138.29 |
Aastane muutus* | 38.07% |
Päeva ulatus* | 137.97 - 139.31 |
52 nädala ulatus | 94.75-144.78 |
Keskmine maht (10 päeva) | 1.87M |
Keskmine maht (3 kuud) | 29.48M |
Turukapitalisatsioon | 242.13B |
P/E suhtarv | 39.39 |
Ringluses olevad aktsiad | 2.28B |
Tulu | 25.50B |
EPS | 3.51 |
Dividendid (% kasumist) | 1.27941 |
Beeta | 0.48 |
Järgmine tuluaruande kuupäev | May 4, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 139.17 | 0.89 | 0.64% | 138.28 | 139.67 | 136.87 |
Feb 6, 2023 | 137.65 | 0.15 | 0.11% | 137.50 | 138.76 | 136.55 |
Feb 3, 2023 | 136.30 | 0.66 | 0.49% | 135.64 | 137.38 | 134.50 |
Feb 2, 2023 | 132.29 | -2.45 | -1.82% | 134.74 | 134.95 | 130.96 |
Feb 1, 2023 | 138.68 | -0.99 | -0.71% | 139.67 | 140.07 | 135.90 |
Jan 31, 2023 | 138.69 | 1.03 | 0.75% | 137.66 | 138.84 | 135.83 |
Jan 30, 2023 | 138.79 | -1.84 | -1.31% | 140.63 | 140.66 | 138.53 |
Jan 27, 2023 | 138.02 | 0.24 | 0.17% | 137.78 | 138.72 | 137.22 |
Jan 26, 2023 | 137.10 | -1.34 | -0.97% | 138.44 | 138.76 | 135.96 |
Jan 25, 2023 | 138.84 | 1.78 | 1.30% | 137.06 | 139.45 | 136.73 |
Jan 24, 2023 | 139.55 | -1.91 | -1.35% | 141.46 | 141.46 | 138.42 |
Jan 23, 2023 | 140.62 | -0.59 | -0.42% | 141.21 | 141.44 | 139.82 |
Jan 20, 2023 | 140.71 | 0.48 | 0.34% | 140.23 | 141.05 | 138.81 |
Jan 19, 2023 | 140.57 | 0.70 | 0.50% | 139.87 | 140.78 | 138.46 |
Jan 18, 2023 | 139.39 | -0.31 | -0.22% | 139.70 | 140.85 | 138.96 |
Jan 17, 2023 | 138.61 | -0.54 | -0.39% | 139.15 | 139.91 | 137.88 |
Jan 13, 2023 | 135.93 | 0.40 | 0.30% | 135.53 | 136.77 | 135.03 |
Jan 12, 2023 | 133.29 | 2.03 | 1.55% | 131.26 | 133.61 | 129.73 |
Jan 11, 2023 | 132.23 | 1.41 | 1.08% | 130.82 | 132.56 | 130.12 |
Jan 10, 2023 | 133.22 | -0.62 | -0.46% | 133.84 | 134.86 | 132.79 |
Novo Nisk Adr Repsg 1 Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kogutulu | 111780 | 111696 | 111831 | 122021 | 126946 | 140800 |
Tulu | 111780 | 111696 | 111831 | 122021 | 126946 | 140800 |
Kulud, Kokku | 17183 | 17632 | 17617 | 19559 | 20932 | 23658 |
Brutokasum | 94597 | 94064 | 94214 | 102462 | 106014 | 117142 |
Kogu tegevuskulu | 63348 | 62729 | 64583 | 69538 | 72820 | 82156 |
Müük/Üldine/admin kulud, kokku | 32630 | 32384 | 33656 | 35301 | 36108 | 40409 |
Uuringud ja arendus | 13643 | 13278 | 13568 | 13477 | 13713 | 16292 |
Depreciation / Amortization | 513 | 586 | 1289 | 856 | 2178 | 1631 |
Ootamatud kulutused (tulu) | 542 | 312 | -6 | 1200 | 477 | 714 |
Other Operating Expenses, Total | -1163 | -1463 | -1541 | -855 | -588 | -548 |
Tulud majandustegevusest | 48432 | 48967 | 47248 | 52483 | 54126 | 58644 |
Intressitulud (kulu), muud tulud, neto | -549 | -219 | 439 | -3757 | -846 | 558 |
Muud, neto | -85 | -68 | -72 | -173 | -150 | -122 |
Netotulu enne makse | 47798 | 48680 | 47615 | 48553 | 53130 | 59080 |
Netotulu pärast makse | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Netotulu enne erikulusid | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Netotulu | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Arvestatav tulu, v a erikulud | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Arvestatav tulu, koos erikuludega | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Jaotuse korrigeerimine | 0 | 0 | ||||
Jaotamisele kuuluv netotulu | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Keskmine jaotamisele kuuluv aktsia kohta | 2534.73 | 2478.09 | 2424.42 | 2378.66 | 2340 | 2303.1 |
Jaotatav EPS, v a erakorralised kulud | 14.9621 | 15.3868 | 15.9329 | 16.3752 | 18.0077 | 20.736 |
Dividends per Share - Common Stock Primary Issue | 9.97126 | 7.09867 | 8.25759 | 8.14263 | 7.92244 | 9.6303 |
Jaotamisele kuuluv normaal-EPS | 15.1318 | 15.4854 | 15.9309 | 16.7799 | 18.1694 | 20.9866 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kogutulu | 33804 | 33041 | 35622 | 38333 | 42031 |
Tulu | 33804 | 33041 | 35622 | 38333 | 42031 |
Kulud, Kokku | 5811 | 5547 | 6059 | 6241 | 6917 |
Brutokasum | 27993 | 27494 | 29563 | 32092 | 35114 |
Kogu tegevuskulu | 18822 | 18262 | 20373 | 24699 | 22884 |
Müük/Üldine/admin kulud, kokku | 9188 | 8905 | 10143 | 12822 | 11153 |
Uuringud ja arendus | 3944 | 3944 | 4252 | 5632 | 5206 |
Other Operating Expenses, Total | -121 | -134 | -81 | 4 | -392 |
Tulud majandustegevusest | 14982 | 14779 | 15249 | 13634 | 19147 |
Intressitulud (kulu), muud tulud, neto | 956 | 138 | -137 | -521 | -1228 |
Netotulu enne makse | 15938 | 14917 | 15112 | 13113 | 17919 |
Netotulu pärast makse | 12623 | 12123 | 12119 | 10892 | 14210 |
Netotulu enne erikulusid | 12623 | 12123 | 12119 | 10892 | 14210 |
Netotulu | 12623 | 12123 | 12119 | 10892 | 14210 |
Arvestatav tulu, v a erikulud | 12623 | 12123 | 12119 | 10892 | 14210 |
Arvestatav tulu, koos erikuludega | 12623 | 12123 | 12119 | 10892 | 14210 |
Jaotamisele kuuluv netotulu | 12623 | 12123 | 12119 | 10892 | 14210 |
Keskmine jaotamisele kuuluv aktsia kohta | 2315.6 | 2306.3 | 2297.3 | 2320.5 | 2283.3 |
Jaotatav EPS, v a erakorralised kulud | 5.45129 | 5.25647 | 5.27532 | 4.69382 | 6.22345 |
Dividends per Share - Common Stock Primary Issue | 0 | 5.78289 | 0 | 3.59917 | 0 |
Jaotamisele kuuluv normaal-EPS | 5.45129 | 5.25647 | 5.27532 | 4.69382 | 6.22345 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Käibevarad kokku | 59766 | 60080 | 59067 | 62456 | 65809 | 85595 |
Raha ja lühiajalised investeeringud | 20699 | 18852 | 15638 | 14966 | 12104 | 16362 |
Cash | 18690 | 18852 | 15638 | 14966 | 12104 | 9597 |
Lühiajalised investeeringud | 2009 | 0 | 6765 | |||
Laekumata arved, neto | 22613 | 21938 | 24836 | 29152 | 32184 | 46799 |
Accounts Receivable - Trade, Net | 20234 | 20165 | 22786 | 24912 | 27734 | 40643 |
Total Inventory | 14341 | 15373 | 16336 | 17641 | 18536 | 19621 |
Prepaid Expenses | 1584 | 1613 | 2053 | |||
Other Current Assets, Total | 529 | 2304 | 204 | 697 | 2985 | 2813 |
Total Assets | 97539 | 102355 | 110769 | 125612 | 144922 | 194508 |
Property/Plant/Equipment, Total - Net | 30179 | 35247 | 41891 | 50551 | 50269 | 55362 |
Property/Plant/Equipment, Total - Gross | 58024 | 64661 | 72438 | 84420 | 86686 | 95887 |
Accumulated Depreciation, Total | -27845 | -29414 | -30547 | -33869 | -36417 | -40525 |
Intangibles, Net | 2714 | 3325 | 5145 | 5835 | 20657 | 38825 |
Long Term Investments | 1508 | 1195 | 1296 | 1444 | 1348 | 1078 |
Note Receivable - Long Term | 689 | 567 | 477 | 1205 | 974 | 630 |
Other Long Term Assets, Total | 2683 | 1941 | 2893 | 4121 | 5865 | 8672 |
Total Current Liabilities | 47436 | 47056 | 54164 | 58983 | 70273 | 99516 |
Accounts Payable | 6011 | 5610 | 6756 | 6358 | 5717 | 8870 |
Accrued Expenses | 11051 | 6799 | 7015 | 478 | 598 | 590 |
Notes Payable/Short Term Debt | 229 | 1694 | 515 | 659 | 6684 | 12862 |
Other Current Liabilities, Total | 30145 | 32953 | 39878 | 50673 | 56499 | 76372 |
Total Liabilities | 52270 | 52540 | 58930 | 68019 | 81597 | 123762 |
Total Long Term Debt | 0 | 0 | 0 | 3009 | 2897 | 12961 |
Deferred Income Tax | 13 | 846 | 118 | 80 | 2502 | 5271 |
Other Liabilities, Total | 4821 | 4638 | 4648 | 5947 | 5925 | 6014 |
Total Equity | 45269 | 49815 | 51839 | 57593 | 63325 | 70746 |
Common Stock | 510 | 500 | 490 | 480 | 470 | 462 |
Retained Earnings (Accumulated Deficit) | 47607 | 48855 | 54102 | 58291 | 63589 | 72934 |
Treasury Stock - Common | -9 | -11 | -11 | -10 | -8 | -6 |
Other Equity, Total | -2839 | 471 | -2742 | -1168 | -726 | -2644 |
Total Liabilities & Shareholders’ Equity | 97539 | 102355 | 110769 | 125612 | 144922 | 194508 |
Total Common Shares Outstanding | 537.436 | 2444 | 2394 | 2352 | 2312.5 | 2276.04 |
Current Port. of LT Debt/Capital Leases | 815 | 775 | 822 | |||
Capital Lease Obligations | 3009 | 2897 | 3307 | |||
Goodwill, Net | 4346 | |||||
Long Term Debt | 9654 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 61389 | 77146 | 91213 | 85595 | 86537 |
Raha ja lühiajalised investeeringud | 7666 | 27216 | 35390 | 17485 | 20146 |
Cash | 5683 | 24229 | 29493 | 10720 | 13394 |
Lühiajalised investeeringud | 1983 | 2987 | 5897 | 6765 | 6752 |
Laekumata arved, neto | 33917 | 30223 | 35452 | 46799 | 44166 |
Accounts Receivable - Trade, Net | 28029 | 26098 | 29860 | 40643 | 36241 |
Total Inventory | 18653 | 18822 | 18899 | 19621 | 20289 |
Other Current Assets, Total | 1153 | 885 | 1472 | 1690 | 1936 |
Total Assets | 141387 | 158095 | 174084 | 194508 | 197136 |
Property/Plant/Equipment, Total - Net | 51429 | 52076 | 52863 | 55362 | 56399 |
Intangibles, Net | 20357 | 20272 | 20526 | 43171 | 43344 |
Long Term Investments | 1749 | 1839 | 1778 | 1441 | 1279 |
Note Receivable - Long Term | 551 | 413 | 332 | 267 | 239 |
Other Long Term Assets, Total | 5912 | 6349 | 7372 | 8672 | 9338 |
Total Current Liabilities | 72384 | 72798 | 88328 | 99516 | 95602 |
Accounts Payable | 6800 | 7616 | 8877 | 8870 | 6679 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 6823 | 1301 | 1350 | 13684 | 1396 |
Other Current Liabilities, Total | 58761 | 63881 | 78101 | 76962 | 87527 |
Total Liabilities | 82891 | 92536 | 107972 | 123762 | 130586 |
Total Long Term Debt | 2832 | 12463 | 12398 | 12961 | 24084 |
Long Term Debt | 2832 | 12463 | 12398 | 12961 | 24084 |
Deferred Income Tax | 1963 | 1818 | 1643 | 5271 | 5305 |
Other Liabilities, Total | 5712 | 5457 | 5603 | 6014 | 5595 |
Total Equity | 58496 | 65559 | 66112 | 70746 | 66550 |
Common Stock | 470 | 462 | 462 | 462 | 462 |
Retained Earnings (Accumulated Deficit) | 58035 | 65100 | 65654 | 70290 | 66095 |
Treasury Stock - Common | -9 | -3 | -4 | -6 | -7 |
Total Liabilities & Shareholders’ Equity | 141387 | 158095 | 174084 | 194508 | 197136 |
Total Common Shares Outstanding | 2272.06 | 2272.06 | 2272.06 | 2276.04 | 2276.04 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netotulu/algväärtus | 37925 | 38130 | 38628 | 38951 | 42138 | 47757 |
Raha majandustegevusest | 48314 | 41168 | 45028 | 46782 | 51951 | 55000 |
Raha majandustegevusest | 3193 | 3182 | 3925 | 5661 | 5753 | 6025 |
Mittelikviidsed varad | 13755 | 12577 | 15085 | 16634 | 18841 | 24332 |
Cash Taxes Paid | 2899 | 9101 | 9614 | 10936 | 10106 | 14438 |
Makstud intressid | 66 | 87 | 89 | 204 | 422 | 261 |
Muutused tööjõus | -6559 | -12721 | -12610 | -14464 | -14781 | -23114 |
Tulu investeeringutelt | -6790 | -6571 | -12080 | -11509 | -22436 | -31605 |
Kapitalikulutused | -8267 | -8648 | -12410 | -11231 | -22081 | -7385 |
Muud rahavood investeeringutelt, kokku | 1477 | 2077 | 330 | -278 | -355 | -24220 |
Rahavood investeeringutelt | -38887 | -35689 | -34521 | -35484 | -32244 | -25493 |
Total Cash Dividends Paid | -23830 | -18844 | -19048 | -19409 | -20121 | -21517 |
Aktsiate emiteerimine (tagasiost), neto | -15057 | -16845 | -15567 | -15334 | -16855 | -19447 |
Muutused valuutakursside kõikumisest | -26 | -211 | 44 | -7 | -456 | 591 |
Rahaline kogumuutus | 2611 | -1303 | -1529 | -218 | -3185 | -1507 |
Laenu väljastamine (kustutamine), neto | 94 | -741 | 4732 | 15471 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 12623 | 24746 | 36865 | 47757 | 14210 |
Cash From Operating Activities | 11255 | 36510 | 58017 | 55000 | 23586 |
Cash From Operating Activities | 1377 | 2594 | 3943 | 6025 | 1650 |
Non-Cash Items | 4349 | 15281 | 23749 | 24332 | 11097 |
Cash Taxes Paid | 5931 | 7808 | 8580 | 14438 | 5260 |
Cash Interest Paid | 50 | 85 | 141 | 261 | 52 |
Changes in Working Capital | -7094 | -6111 | -6540 | -23114 | -3371 |
Cash From Investing Activities | -3481 | -6367 | -11002 | -31605 | -1907 |
Capital Expenditures | -1499 | -3383 | -5071 | -7385 | -1780 |
Other Investing Cash Flow Items, Total | -1982 | -2984 | -5931 | -24220 | -127 |
Cash From Financing Activities | -14475 | -18311 | -30042 | -25493 | -19135 |
Financing Cash Flow Items | 2329 | 2737 | |||
Total Cash Dividends Paid | -13495 | -13496 | -21517 | -21517 | -15690 |
Issuance (Retirement) of Stock, Net | -2960 | -8400 | -11935 | -19447 | -4477 |
Issuance (Retirement) of Debt, Net | -349 | 3585 | 3410 | 15471 | -1705 |
Foreign Exchange Effects | 154 | 169 | 291 | 591 | -55 |
Net Change in Cash | -6547 | 12001 | 17264 | -1507 | 2489 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Renaissance Technologies LLC | Hedge Fund | 0.8783 | 15308871 | -2220800 | 2022-09-30 | HIGH |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 0.6271 | 10930506 | 413285 | 2022-09-30 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 0.5178 | 9026001 | -306861 | 2022-12-31 | LOW |
Capital International Investors | Investment Advisor | 0.3603 | 6279859 | 58068 | 2022-09-30 | LOW |
Fayez Sarofim & Co. | Investment Advisor | 0.2994 | 5218104 | 450280 | 2022-09-30 | LOW |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 0.297 | 5177389 | -138349 | 2022-09-30 | LOW |
Managed Account Advisors LLC | Investment Advisor | 0.2562 | 4465925 | 184833 | 2022-09-30 | LOW |
Folketrygdfondet | Pension Fund | 0.2446 | 4262659 | 119781 | 2022-09-30 | LOW |
WCM Investment Management | Investment Advisor | 0.2161 | 3766983 | -83070 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2025 | 3528815 | -27044 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 0.1996 | 3479090 | 0 | 2022-09-30 | LOW |
Everett Harris & Co. | Investment Advisor | 0.1904 | 3319309 | 3219 | 2022-12-31 | LOW |
BofA Global Research (US) | Research Firm | 0.1638 | 2855711 | -16615 | 2022-09-30 | LOW |
Parametric Portfolio Associates LLC | Investment Advisor | 0.1521 | 2651790 | 56485 | 2022-09-30 | LOW |
Envestnet Asset Management, Inc. | Investment Advisor | 0.1035 | 1804466 | -3165 | 2022-09-30 | LOW |
Northern Trust Global Investments | Investment Advisor | 0.1016 | 1771364 | -24950 | 2022-09-30 | LOW |
Aperio Group, LLC | Investment Advisor | 0.0938 | 1635017 | -39785 | 2022-09-30 | LOW |
Wells Fargo Advisors | Research Firm | 0.0902 | 1573006 | -182638 | 2022-09-30 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 0.0855 | 1490734 | 12584 | 2022-09-30 | LOW |
BlackRock Investment Management, LLC | Investment Advisor/Hedge Fund | 0.0854 | 1488034 | -41020 | 2022-09-30 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com GroupKauplejad
Igakuiste aktiivsete klientide arv
Igakuine investeerimise maht
Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Nordisk ADR Company profile
Ettevõttest Novo Nisk Adr Repsg 1
Novo Nordisk A/S on ülemaailmne tervishoiuettevõte, mis tegeleb diabeedi ravimisega. Ettevõte tegeleb ka farmaatsiatoodete väljatöötamise, arendamise, tootmise ja turustamisega. Ettevõte tegutseb kahes ärisegmendis: diabeedi ja rasvumise ravi ning biofarmatseutilised ravimid. Ettevõtte diabeedi ja rasvumise ravi segment hõlmab insuliini, GLP-1, muid valkudega seotud tooteid, nagu glükagoon, valkudega seotud manustamissüsteemid ja nõelad ning suukaudsed diabeedivastased ravimid. Ettevõtte biofarmatseutiliste ravimite segment hõlmab hemofiilia ravi, kasvuhormoonravi ja hormoonasendusravi ravivaldkondi. Ettevõte pakub ka Saxenda toodet rasvumise raviks. Ettevõte pakub erinevaid tooteid, sealhulgas NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin ja Vagifem. Seisuga 31. detsember 2016 turustas ta oma tooteid enam kui 180 riigis. Tema piirkondlik struktuur koosneb kahest äriüksusest: Põhja-Ameerika ja rahvusvaheline tegevus.
Industry: | Pharmaceuticals (NEC) |
Novo Alle 1
BAGSVAERD
2880
DK
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com